Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19

Zou, Caifeng; Huang, Yuting; Ma, Yuchi; Yang, Feng; Fu, Deliang

doi:10.1016/j.ejca.2021.04.011

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. 24 From our case series, the first patient was treated surgically whilst the second patient was treated conservatively. The latter patient was not suitable for surgical intervention in view of bilateral widespread bullous lung disease and increased risk of pneumothorax and hypoxemia during single lung ventilation.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Development of bullous lung disease with pneumothorax following SARS‐CoV‐2 infection

Abdullah

Wong

Ibrahim

et al. 2022

Respirology Case Reports

View full text Add to dashboard Cite

Cystic lung formation secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was described during coronavirus disease pandemic, but with relatively low prevalence. A rare yet under-recognized complication is that these cystic areas may progress to bullae, cavities and pneumothorax. We reported two cases of ruptured bullae with pneumothorax following SARS-CoV-2 infection. Two patients were discharged following SARS-CoV-2 pneumonia, which did not require invasive mechanical ventilation (IMV). However, both patients presented again a month later with shortness of breath. Repeated computed tomography (CT) thorax showed development of bullous lung disease and pneumothorax. The first patient underwent surgical intervention whilst the second patient was treated conservatively. Development of bullous lung disease following SARS-CoV-2 infection is rare but may be associated with serious morbidity. Patients whose general condition permits should be offered surgical intervention whilst conservative management is reserved for non-surgical candidates.

show abstract

Section: Discussionmentioning

confidence: 94%

“…Timing of surgery in these cases must be individualized, considering the nature and risk level of the intended surgery, co‐morbidities, and the risk associated with delay of surgery. When possible, surgery should be delayed for at least 7 weeks following SARS‐CoV‐2 infection 24 …”

Section: Discussionmentioning

confidence: 99%

Development of bullous lung disease with pneumothorax following SARS‐CoV‐2 infection

Abdullah

Wong

Ibrahim

et al. 2022

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

“…The results of the meta-analysis did not show such a relationship in the case of molecularly targeted therapy, immunotherapy, or radiotherapy. In turn, many studies, including meta-analyses, have confirmed the negative impact of active SARS-CoV-2 infection during the postoperative period in cancer patients treated with surgery [8,9].…”

Section: Effect Of Anticancer Treatment Typementioning

confidence: 99%

Recommendations for prevention of SARS-CoV-2 infection in immunocompromised patients

et al. 2023

View full text Add to dashboard Cite

“…There were no safety concerns surrounding immunotherapy, targeted therapies, surgery, and radiotherapy (however, the authors and Zou et al exchanged letters clarifying which surgical patients were included in the study). [12][13][14] The common denominator among these studies is the investigators' call for additional research. Realistically, they write, it may take years to establish a clear association between COVID-19 and cancer progression, but that makes it even more important to focus on research now.…”

Section: Ultra-comprehensive Genomic Profiling With a Spotlight On Wh...mentioning

confidence: 99%

Amid Concerns, Will Practices Take Part in the Enhancing Oncology Model?

2023

Am J Manag Care

View full text Add to dashboard Cite

THREE MONTHS FROM NOW, the Enhancing Oncology Model (EOM) will go live, based on a timeline announced last summer by the Center for Medicare & Medicaid Innovation (CMMI). 1 It will be the most important milestone in value-based cancer care since the start of its predecessor, the Oncology Care Model (OCM), in 2016. 2 Practices have learned plenty since that initial deep dive into the world of alternative payment models (APMs), and successful OCM participants say they would never return to the old way of delivering care. When the OCM concluded on June 30, 2022, several practices touted improved outcomes and patient experience-and for some, Medicare savings-achieved with help from navigators, use of data

show abstract

Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19

Cited by 4 publications

References 10 publications

Development of bullous lung disease with pneumothorax following SARS‐CoV‐2 infection

Development of bullous lung disease with pneumothorax following SARS‐CoV‐2 infection

Recommendations for prevention of SARS-CoV-2 infection in immunocompromised patients

Amid Concerns, Will Practices Take Part in the Enhancing Oncology Model?

Contact Info

Product

Resources

About